My latest article, originally published in The BMJ on 30 Dec 2022, reports on the “Record4 trial,” which tested the anti-clotting drug, rivaroxaban (XARELTO®). The drug was initially approved in the US and the EU for the prevention of deep vein thrombosis following hip & knee replacement, but regulators later